Julkaisuja vuodelta 2021

  1. Kohtamäki, L, Arjama, M, Mäkelä, S, Ianevski, P, Välimäki, K, Juteau, S et al.. High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Transl Oncol. 2021;15 (1):101290. doi: 10.1016/j.tranon.2021.101290. PubMed PMID:34837846 .
  2. Ungureanu, D, Țăranu, N, Ghiga, DA, Isopescu, DN, Mihai, P, Cozmanciuc, R et al.. Diagonal Tensile Test on Masonry Panels Strengthened with Textile-Reinforced Mortar. Materials (Basel). 2021;14 (22):. doi: 10.3390/ma14227021. PubMed PMID:34832431 PubMed Central PMC8622034.
  3. Vettenranta, A, Murtola, TJ, Raitanen, J, Raittinen, P, Talala, K, Taari, K et al.. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncol. 2021; :. doi: 10.1001/jamaoncol.2021.5672. PubMed PMID:34817559 .
  4. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Sauna habits/bathing and changes in lower urinary tract symptoms – Tampere Ageing Male Urologic Study (TAMUS). Scand J Urol. 2021; :1-6. doi: 10.1080/21681805.2021.2002403. PubMed PMID:34783288 .
  5. Loukovaara, S, Auvinen, A, Haukka, J. Associations between systemic medications and development of wet age-related macular degeneration. Acta Ophthalmol. 2021; :. doi: 10.1111/aos.15056. PubMed PMID:34779110 .
  6. Lupășteanu, V, Ungureanu, D, Țăranu, N, Isopescu, DN, Lupășteanu, R, Mihai, P et al.. Structural Response of Bonded Joints between FRP Composite Strips and Steel Plates. Materials (Basel). 2021;14 (21):. doi: 10.3390/ma14216722. PubMed PMID:34772248 PubMed Central PMC8588173.
  7. Ventelä, J, Nikkilä, A, Jukkola, A, Lohi, O. Incidence and outcomes of cancer in 16- to 17-year-old adolescents. Acta Paediatr. 2021; :. doi: 10.1111/apa.16161. PubMed PMID:34689375 .
  8. Emmert-Streib, F, Manjang, K, Dehmer, M, Yli-Harja, O, Auvinen, A. Are There Limits in Explainability of Prognostic Biomarkers? Scrutinizing Biological Utility of Established Signatures. Cancers (Basel). 2021;13 (20):. doi: 10.3390/cancers13205087. PubMed PMID:34680236 PubMed Central PMC8533990.
  9. Auvinen, A, Cardis, E, Blettner, M, Moissonnier, M, Sadetzki, S, Giles, G et al.. Diagnostic radiological examinations and risk of intracranial tumours in adults-findings from the Interphone Study. Int J Epidemiol. 2021; :. doi: 10.1093/ije/dyab140. PubMed PMID:34648614 .
  10. Beyer, K, MacLennan, SJ, Moris, L, Lardas, M, Mastris, K, Hooker, G et al.. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. Eur Urol Focus. 2021;7 (5):943-946. doi: 10.1016/j.euf.2021.09.008. PubMed PMID:34602368 .
  11. Li, QK, Chen, J, Hu, Y, Höti, N, Lih, TM, Thomas, SN et al.. Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors. Sci Rep. 2021;11 (1):18936. doi: 10.1038/s41598-021-98410-0. PubMed PMID:34556748 PubMed Central PMC8460832.
  12. Taavitsainen, S, Engedal, N, Cao, S, Handle, F, Erickson, A, Prekovic, S et al.. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun. 2021;12 (1):5307. doi: 10.1038/s41467-021-25624-1. PubMed PMID:34489465 PubMed Central PMC8421417.
  13. Barchuk, A, Tursun-Zade, R, Belayev, A, Moore, M, Komarov, Y, Moshina, N et al.. Comparability and validity of cancer registry data in the northwest of Russia. Acta Oncol. 2021;60 (10):1264-1271. doi: 10.1080/0284186X.2021.1967443. PubMed PMID:34424113 .
  14. Soronen, V, Talala, K, Raitanen, J, Taari, K, Tammela, T, Auvinen, A et al.. Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial. Scand J Urol. 2021;55 (5):348-353. doi: 10.1080/21681805.2021.1966095. PubMed PMID:34409927 .
  15. van Tilburg, CM, Pfaff, E, Pajtler, KW, Langenberg, KPS, Fiesel, P, Jones, BC et al.. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021;11 (11):2764-2779. doi: 10.1158/2159-8290.CD-21-0094. PubMed PMID:34373263 .
  16. Jacome Sanz, D, Raivola, J, Karvonen, H, Arjama, M, Barker, H, Murumägi, A et al.. Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers (Basel). 2021;13 (15):. doi: 10.3390/cancers13153727. PubMed PMID:34359627 PubMed Central PMC8345177.
  17. Ketola, K, Kaljunen, H, Taavitsainen, S, Kaarijärvi, R, Järvelä, E, Rodríguez-Martín, B et al.. Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. Cancer Res. 2021;81 (19):4901-4909. doi: 10.1158/0008-5472.CAN-21-0371. PubMed PMID:34348967 .
  18. Jasu, J, Tolonen, T, Antonarakis, ES, Beltran, H, Halabi, S, Eisenberger, MA et al.. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021;30 :47-62. doi: 10.1016/j.euros.2021.05.011. PubMed PMID:34337548 PubMed Central PMC8317817.
  19. Walter, SD, Hu, J, Talala, K, Tammela, T, Taari, K, Auvinen, A et al.. Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer. Cancer Causes Control. 2021;32 (11):1299-1313. doi: 10.1007/s10552-021-01480-8. PubMed PMID:34313874 .
  20. Kukkonen, K, Taavitsainen, S, Huhtala, L, Uusi-Makela, J, Granberg, KJ, Nykter, M et al.. Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response. Cancers (Basel). 2021;13 (13):. doi: 10.3390/cancers13133325. PubMed PMID:34283056 PubMed Central PMC8268970.
  21. Wollschläger, D, Auvinen, A, Blettner, M, Zeeb, H. Methodological considerations for interrupted time series analysis in radiation epidemiology: an overview. J Radiol Prot. 2021;41 (4):. doi: 10.1088/1361-6498/ac149c. PubMed PMID:34261051 .
  22. Immonen, E, Nikkilä, A, Peltomäki, T, Aine, L, Lohi, O. Late adverse effects of childhood acute lymphoblastic leukemia treatment on developing dentition. Pediatr Blood Cancer. 2021;68 (9):e29200. doi: 10.1002/pbc.29200. PubMed PMID:34228397 .
  23. Jacome Sanz, D, Saralahti, AK, Pekkarinen, M, Kesseli, J, Nykter, M, Rämet, M et al.. Proprotein convertase subtilisin/kexin type 9 regulates the production of acute-phase reactants from the liver. Liver Int. 2021;41 (10):2511-2522. doi: 10.1111/liv.14993. PubMed PMID:34174143 .
  24. Meng, B, Kemp, SA, Papa, G, Datir, R, Ferreira, IATM, Marelli, S et al.. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021;35 (13):109292. doi: 10.1016/j.celrep.2021.109292. PubMed PMID:34166617 PubMed Central PMC8185188.
  25. Raittinen, PVH, Syvälä, H, Tammela, TLJ, Häkkinen, MR, Ilmonen, P, Auriola, S et al.. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine. 2021;68 :103432. doi: 10.1016/j.ebiom.2021.103432. PubMed PMID:34144486 PubMed Central PMC8219992.
  26. Launonen, KM, Paakinaho, V, Sigismondo, G, Malinen, M, Sironen, R, Hartikainen, JM et al.. Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells. Oncogene. 2021;40 (27):4567-4579. doi: 10.1038/s41388-021-01887-2. PubMed PMID:34127815 PubMed Central PMC8266679.
  27. Annala, M, Taavitsainen, S, Khalaf, DJ, Vandekerkhove, G, Beja, K, Sipola, J et al.. Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clin Cancer Res. 2021;27 (16):4610-4623. doi: 10.1158/1078-0432.CCR-21-1625. PubMed PMID:34083234 .
  28. Mäkinen, A, Nikkilä, A, Mehtonen, J, Teppo, S, Oksa, L, Nordlund, J et al.. Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis. Pathology. 2021;53 (7):875-882. doi: 10.1016/j.pathol.2021.02.013. PubMed PMID:34049715 .
  29. Sipeky, C, Tammela, TLJ, Auvinen, A, Schleutker, J. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer Prostatic Dis. 2021;24 (4):1158-1166. doi: 10.1038/s41391-021-00378-5. PubMed PMID:34012061 .
  30. Filppu, P, Tanjore Ramanathan, J, Granberg, KJ, Gucciardo, E, Haapasalo, H, Lehti, K et al.. CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity. JCI Insight. 2021;6 (9):. doi: 10.1172/jci.insight.141486. PubMed PMID:33986188 PubMed Central PMC8262342.
  31. Eerola, SK, Kohvakka, A, Tammela, TLJ, Koskinen, PJ, Latonen, L, Visakorpi, T et al.. Expression and ERG regulation of PIM kinases in prostate cancer. Cancer Med. 2021;10 (10):3427-3436. doi: 10.1002/cam4.3893. PubMed PMID:33932111 PubMed Central PMC8124112.
  32. Rajamäki, K, Taira, A, Katainen, R, Välimäki, N, Kuosmanen, A, Plaketti, RM et al.. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer. Gastroenterology. 2021;161 (2):592-607. doi: 10.1053/j.gastro.2021.04.042. PubMed PMID:33930428 .
  33. Cangiano, M, Grudniewska, M, Salji, MJ, Nykter, M, Jenster, G, Urbanucci, A et al.. Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer. Cancers (Basel). 2021;13 (9):. doi: 10.3390/cancers13092094. PubMed PMID:33925994 PubMed Central PMC8123677.
  34. Mäkinen, A, Nikkilä, A, Haapaniemi, T, Oksa, L, Mehtonen, J, Vänskä, M et al.. IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia. Cancers (Basel). 2021;13 (7):. doi: 10.3390/cancers13071505. PubMed PMID:33805930 PubMed Central PMC8037952.
  35. Vettenranta, A, Murtola, TJ, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of prostate cancer screening among men using antidiabetic medication. Sci Rep. 2021;11 (1):7363. doi: 10.1038/s41598-021-86534-2. PubMed PMID:33795720 PubMed Central PMC8016840.
  36. Peltomaa, AI, Raittinen, P, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study. Prostate Cancer Prostatic Dis. 2021;24 (3):917-924. doi: 10.1038/s41391-021-00351-2. PubMed PMID:33790420 PubMed Central PMC8384625.
  37. Collier, DA, De Marco, A, Ferreira, IATM, Meng, B, Datir, RP, Walls, AC et al.. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593 (7857):136-141. doi: 10.1038/s41586-021-03412-7. PubMed PMID:33706364 .
  38. Vihervuori, VJ, Talala, K, Taari, K, Lahtela, J, Tammela, TLJ, Auvinen, A et al.. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiol Biomarkers Prev. 2021;30 (5):982-989. doi: 10.1158/1055-9965.EPI-19-0580. PubMed PMID:33653815 .
  39. Salminen, JK, Kuoppamäki, V, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2021;149 (2):307-315. doi: 10.1002/ijc.33535. PubMed PMID:33634851 .
  40. Khan, MW, Juutilainen, J, Auvinen, A, Naarala, J, Pukkala, E, Roivainen, P et al.. A cohort study on adult hematological malignancies and brain tumors in relation to magnetic fields from indoor transformer stations. Int J Hyg Environ Health. 2021;233 :113712. doi: 10.1016/j.ijheh.2021.113712. PubMed PMID:33601135 .
  41. Winter, G, Kirschner-Schwabe, R, Groeneveld-Krentz, S, Escherich, G, Möricke, A, von Stackelberg, A et al.. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome. Leukemia. 2021;35 (5):1475-1479. doi: 10.1038/s41375-021-01163-y. PubMed PMID:33580201 PubMed Central PMC8102191.
  42. Beyer, K, Moris, L, Lardas, M, Haire, A, Barletta, F, Scuderi, S et al.. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open. 2021;11 (2):e040531. doi: 10.1136/bmjopen-2020-040531. PubMed PMID:33574142 PubMed Central PMC7880102.
  43. Siltari, A, Auvinen, A, Murtola, TJ. Pharmacoepidemiological Evaluation in Prostate Cancer-Common Pitfalls and How to Avoid Them. Cancers (Basel). 2021;13 (4):. doi: 10.3390/cancers13040696. PubMed PMID:33572236 PubMed Central PMC7914977.
  44. Lange, J, Remmers, S, Gulati, R, Bill-Axelson, A, Johansson, JE, Kwiatkowski, M et al.. Impact of cancer screening on metastasis: A prostate cancer case study. J Med Screen. 2021;28 (4):480-487. doi: 10.1177/0969141321989738. PubMed PMID:33563084 PubMed Central PMC8349931.
  45. Kemp, SA, Collier, DA, Datir, RP, Ferreira, IATM, Gayed, S, Jahun, A et al.. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592 (7853):277-282. doi: 10.1038/s41586-021-03291-y. PubMed PMID:33545711 PubMed Central PMC7610568.
  46. Murumägi, A, Ungureanu, D, Arjama, M, Bützow, R, Lohi, J, Sariola, H et al.. STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells. Transl Oncol. 2021;14 (4):101027. doi: 10.1016/j.tranon.2021.101027. PubMed PMID:33530027 PubMed Central PMC7851186.
  47. Neupane, S, Nevalainen, J, Raitanen, J, Talala, K, Kujala, P, Taari, K et al.. Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers (Basel). 2021;13 (3):. doi: 10.3390/cancers13030435. PubMed PMID:33498854 PubMed Central PMC7865328.
  48. Conti, DV, Darst, BF, Moss, LC, Saunders, EJ, Sheng, X, Chou, A et al.. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53 (3):413. doi: 10.1038/s41588-021-00786-2. PubMed PMID:33473200 .
  49. Cerqueira, JXM, Saavalainen, P, Kurppa, K, Laurikka, P, Huhtala, H, Nykter, M et al.. Independent and cumulative coeliac disease-susceptibility loci are associated with distinct disease phenotypes. J Hum Genet. 2021;66 (6):613-623. doi: 10.1038/s10038-020-00888-5. PubMed PMID:33446885 PubMed Central PMC8144013.
  50. Karlsson, Q, Brook, MN, Dadaev, T, Wakerell, S, Saunders, EJ, Muir, K et al.. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. Eur Urol Oncol. 2021;4 (4):570-579. doi: 10.1016/j.euo.2020.12.001. PubMed PMID:33436325 PubMed Central PMC8381233.
  51. Alanko, J, Tanner, M, Vanninen, R, Auvinen, A, Isola, J. Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast Cancer Res Treat. 2021;187 (1):267-274. doi: 10.1007/s10549-020-06060-z. PubMed PMID:33420595 PubMed Central PMC8062374.
  52. Vandekerkhove, G, Lavoie, JM, Annala, M, Murtha, AJ, Sundahl, N, Walz, S et al.. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021;12 (1):184. doi: 10.1038/s41467-020-20493-6. PubMed PMID:33420073 PubMed Central PMC7794518.
  53. Conti, DV, Darst, BF, Moss, LC, Saunders, EJ, Sheng, X, Chou, A et al.. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53 (1):65-75. doi: 10.1038/s41588-020-00748-0. PubMed PMID:33398198 PubMed Central PMC8148035.
  54. Valkonen, M, Hognas, G, Bova, GS, Ruusuvuori, P. Generalized Fixation Invariant Nuclei Detection Through Domain Adaptation Based Deep Learning. IEEE J Biomed Health Inform. 2021;25 (5):1747-1757. doi: 10.1109/JBHI.2020.3039414. PubMed PMID:33211668 .
  55. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cancer. 2021;127 (2):188-192. doi: 10.1002/cncr.33254. PubMed PMID:33048394 .
  56. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Seasonal changes in occurrence and severity of lower urinary tract symptoms-Tampere Aging Male Urologic Study (TAMUS). Low Urin Tract Symptoms. 2021;13 (2):216-223. doi: 10.1111/luts.12353. PubMed PMID:33034153 .
  57. Tomer, A, Nieboer, D, Roobol, MJ, Bjartell, A, Steyerberg, EW, Rizopoulos, D et al.. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU Int. 2021;127 (1):96-107. doi: 10.1111/bju.15136. PubMed PMID:32531869 PubMed Central PMC7818468.

Search PubMed